Immunovant

Summary

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

History

Immunovant was founded in July 2016 with a focus on leveraging the power of FcRn biology to develop innovative therapies for autoimmune diseases. In June 2017, the company entered into a partnership with Genentech, which granted the company access to a portfolio of FcRn-targeting antibodies from three distinct classes. In September 2018, Immunovant entered into a collaboration with AbbVie. Through this partnership, Immunovant acquired exclusive rights to develop and commercialize certain AbbVie products for the treatment of certain autoimmune diseases.

Mission

Our mission is to develop innovative therapies to improve the lives of patients suffering from autoimmune diseases and other disorders.

Vision

At Immunovant, our vision is to be a trusted partner in autoimmune disease research, discovery and development and to deliver our therapies with the highest standards of quality and innovation.

References

https://in.investing.com/equities/immunovant-inc

https://finance.yahoo.com/quote/IMVT/profile?p=IMVT

https://www.crunchbase.com/organization/immunovant

https://sec.report/CIK/0001764013

https://companiesmarketcap.com/

https://immunovant.com

Contacts

Follow Us

Immunovant

Share

Contacts

Follow Us